Volume 70, Issue 4, Pages 684-691 (April 2019) Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial Joong-Won Park, Yoon Jun Kim, Do Young Kim, Si-Hyun Bae, Seung Woon Paik, Youn-Jae Lee, Hwi Young Kim, Han Chu Lee, Sang Young Han, Jae Youn Cheong, Oh Sang Kwon, Jong Eun Yeon, Bo Hyun Kim, Jaeseok Hwang Journal of Hepatology Volume 70, Issue 4, Pages 684-691 (April 2019) DOI: 10.1016/j.jhep.2018.11.029 Copyright © 2018 European Association for the Study of the Liver Terms and Conditions
Journal of Hepatology 2019 70, 684-691DOI: (10. 1016/j. jhep. 2018. 11 Copyright © 2018 European Association for the Study of the Liver Terms and Conditions
Fig. 1 Consort flow diagram. cTACE, conventional transarterial chemoembolization. Journal of Hepatology 2019 70, 684-691DOI: (10.1016/j.jhep.2018.11.029) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions
Fig. 2 Kaplan-Meier curves of overall survival, time to progression, and progression-free survival for the intention-to-treat population. HR, hazard ratio; OS, overall survival. Journal of Hepatology 2019 70, 684-691DOI: (10.1016/j.jhep.2018.11.029) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions
Fig. 3 Forest plots showing subgroup analyses of overall survival. AFP, alpha-fetoprotein; cTACE, conventional transarterial chemoembolization; UICC, Union for International Cancer Control. Journal of Hepatology 2019 70, 684-691DOI: (10.1016/j.jhep.2018.11.029) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions